Navigation

TNKase (Genentech Inc)

TNKase (Genentech Inc) - General Information

Tissue plasminogen activator (tPA). TNKase (Genentech Inc) is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.

 

Pharmacology of TNKase (Genentech Inc)

Cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

 

TNKase (Genentech Inc) for patients

 

TNKase (Genentech Inc) Interactions

Formal interaction studies of TNKase with other drugs have not been performed. Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.

Drug/Laboratory Test Interactions

During TNKase therapy, results of coagulation tests and/or measures of fibrinolytic activity may be unreliable unless specific precautions are taken to prevent in vitro artifacts. Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions. This can lead to degradation of fibrinogen in blood samples removed for analysis.

 

TNKase (Genentech Inc) Contraindications

TNKase therapy in patients with acute myocardial infarction is contraindicated in the following situations because of an increased risk of bleeding:

 

Additional information about TNKase (Genentech Inc)

TNKase (Genentech Inc) Indication: For treatment of myocardial infarction and lysis of intracoronary emboli
Mechanism Of Action: TNKase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Tenecteplase
Synonyms: Tissue-type plasminogen activator precursor; t- PA; t-plasminogen activator; tPA
Drug Category: Thrombolytic Agents
Drug Type: Biotech; Approved

Other Brand Names containing Tenecteplase: TNKase (Genentech Inc);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 1.9 hours (mammalian reticulocytes, in vitro)
>20 hours (yeast, in vivo)
>10 hours (Escherichia coli, in vivo)
Dosage Forms of TNKase (Genentech Inc): Powder, for solution Intravenous
Chemical IUPAC Name: Human tissue plasminogen activator
Chemical Formula: C2561H3919N747O781S40
Tenecteplase on Wikipedia: https://en.wikipedia.org/wiki/Tenecteplase
Organisms Affected: Humans and other mammals